{"url_path":"/sec/alzn/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","accession_number":"0001214659-26-008832","cik":"0001677077","ticker":"ALZN","issuer_name":"Alzamend Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1677077/0001214659-26-008832-index.html","primary_entity_key":"0001677077","primary_entity_name":"Alzamend Neuro, Inc."},"word_count":1331,"has_tables":true,"body_markdown":"false\n2026\nFY\n0001677077\n\n0001677077\n\n2025-05-01\n2026-04-30\n\n0001677077\n\n2025-10-31\n\n0001677077\n\n2026-07-22\n\n0001677077\n\n2026-02-01\n2026-04-30\n\n0001677077\n\nalzn:StephanJackmanMember\n\n2026-04-30\n\n0001677077\n\nalzn:StephanJackman1Member\n\n2026-04-30\n\n0001677077\n\nalzn:DavidJ.KatzoffMember\n\n2026-04-30\n\n0001677077\n\nalzn:DavidJ.Katzoff1Member\n\n2026-04-30\n\n0001677077\n\nalzn:DavidJ.Katzoff2Member\n\n2026-04-30\n\n0001677077\n\nalzn:DavidJ.Katzoff3Member\n\n2026-04-30\n\n0001677077\n\nalzn:DavidJ.Katzoff4Member\n\n2026-04-30\n\n0001677077\n\n2026-04-30\n\n0001677077\n\n2025-04-30\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-04-30\n\n0001677077\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:SeriesAConvertiblePreferredStockMember\n\n2024-04-30\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\n\n2024-04-30\n\n0001677077\n\nalzn:SeriesCConvertiblePreferredStockMember\n\n2024-04-30\n\n0001677077\n\nus-gaap:CommonStockMember\n\n2024-04-30\n\n0001677077\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-04-30\n\n0001677077\n\nus-gaap:RetainedEarningsMember\n\n2024-04-30\n\n0001677077\n\n2024-04-30\n\n0001677077\n\nalzn:SeriesAConvertiblePreferredStockMember\n\n2025-04-30\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\n\n2025-04-30\n\n0001677077\n\nalzn:SeriesCConvertiblePreferredStockMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:CommonStockMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:RetainedEarningsMember\n\n2025-04-30\n\n0001677077\n\nalzn:SeriesAConvertiblePreferredStockMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:SeriesCConvertiblePreferredStockMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:CommonStockMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:RetainedEarningsMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:SeriesAConvertiblePreferredStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:SeriesCConvertiblePreferredStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:CommonStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:RetainedEarningsMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:SeriesAConvertiblePreferredStockMember\n\n2026-04-30\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\n\n2026-04-30\n\n0001677077\n\nalzn:SeriesCConvertiblePreferredStockMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:CommonStockMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:RetainedEarningsMember\n\n2026-04-30\n\n0001677077\n\nalzn:AtTheMarketMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\n2026-01-31\n\n0001677077\n\nus-gaap:StockOptionMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:StockOptionMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:DirectorsAndOfficersLiabilityInsuranceMember\n\n2024-06-14\n\n0001677077\n\n2023-05-01\n2024-04-30\n\n0001677077\n\nalzn:FederalMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:CaliforniaFranchiseTaxBoardMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:NorthCarolinaMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:OtherMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:StateAndLocalJurisdictionMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:DomesticCountryMember\n\n2026-04-30\n\n0001677077\n\nalzn:StockIncentivePlan2016Member\n\n2016-04-30\n\n0001677077\n\nalzn:StockIncentivePlan2016Member\n\n2019-02-28\n2019-03-01\n\n0001677077\n\nalzn:StockIncentivePlan2016Member\n\n2016-04-29\n2016-04-30\n\n0001677077\n\nalzn:StockIncentivePlan2021Member\n\n2021-02-28\n\n0001677077\n\nalzn:StockIncentivePlan2021Member\n\n2021-02-01\n2021-02-28\n\n0001677077\n\nalzn:EmployeesAndDirectorsMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:PerformanceContingentStockOptionsMember\nalzn:KeyEmployeesAndDirectorMember\n\n2019-11-25\n2019-11-26\n\n0001677077\n\nalzn:UnamortizedStockBasedCompensationMember\n\n2026-04-30\n\n0001677077\n\nalzn:StockBasedCompensationMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:ResearchAndDevelopmentExpensesMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:ResearchAndDevelopmentExpensesMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:GeneralAndAdministrativeExpensesMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:GeneralAndAdministrativeExpensesMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:Warrant2026Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant2025Member\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:Warrant2025Member\n\n2025-04-30\n\n0001677077\n\nalzn:Warrant1Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant1Member\n\n2026-04-30\n\n0001677077\n\nalzn:Warrant2Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant2Member\n\n2026-04-30\n\n0001677077\n\nalzn:Warrant3Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant3Member\n\n2026-04-30\n\n0001677077\n\nalzn:Warrant4Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant4Member\n\n2026-04-30\n\n0001677077\n\nalzn:Warrant5Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant5Member\n\n2026-04-30\n\n0001677077\n\nalzn:Warrant6Member\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:Warrant6Member\n\n2026-04-30\n\n0001677077\n\nalzn:ExercisePrice1Member\n\n2026-04-30\n\n0001677077\n\nalzn:ExercisePrice2Member\n\n2026-04-30\n\n0001677077\n\nalzn:ExercisePrice3Member\n\n2026-04-30\n\n0001677077\n\nalzn:ExercisePrice4Member\n\n2026-04-30\n\n0001677077\n\nsrt:MinimumMember\n\n2026-04-30\n\n0001677077\n\nsrt:MaximumMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2026-04-30\n\n0001677077\n\nus-gaap:WarrantMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputOptionVolatilityMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2025-04-30\n\n0001677077\n\nus-gaap:WarrantMember\nus-gaap:MeasurementInputExpectedDividendRateMember\n\n2025-04-30\n\n0001677077\n\nalzn:AL001LicenseMember\n\n2018-07-01\n2018-07-02\n\n0001677077\n\nalzn:AL001LicenseMember\nalzn:FirstAnniversaryMember\n\n2018-07-01\n2018-07-02\n\n0001677077\n\nalzn:AL001LicenseMember\nalzn:SecondAnniversaryMember\n\n2018-07-01\n2018-07-02\n\n0001677077\n\nalzn:AL001LicenseMember\nalzn:ThirdAnniversaryMember\n\n2018-07-01\n2018-07-02\n\n0001677077\n\nalzn:ALZN002LicenseMember\n\n2016-04-29\n2016-05-02\n\n0001677077\n\nalzn:ALZN002LicenseMember\nalzn:FirstAnniversaryMember\n\n2016-04-29\n2016-05-02\n\n0001677077\n\nalzn:ALZN002LicenseMember\nalzn:SecondAnniversaryMember\n\n2016-04-29\n2016-05-02\n\n0001677077\n\nalzn:ALZN002LicenseMember\nalzn:ThirdAnniversaryMember\n\n2016-04-29\n2016-05-02\n\n0001677077\n\nalzn:AdditionalAL001LicenseMember\n\n2019-11-01\n2019-11-19\n\n0001677077\n\nalzn:AdditionalAL001LicenseMember\nalzn:FirstAnniversaryMember\n\n2019-11-01\n2019-11-19\n\n0001677077\n\nalzn:AdditionalAL001LicenseMember\nalzn:SecondAnniversaryMember\n\n2019-11-01\n2019-11-19\n\n0001677077\n\nalzn:AdditionalAL001LicenseMember\nalzn:ThirdAnniversaryMember\n\n2019-11-01\n2019-11-19\n\n0001677077\n\nalzn:PreIndMeetingMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:PreIndMeetingMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:IndApplicationFilingMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:IndApplicationFilingMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFirstDosingOfPatientInClinicalTrialMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFirstDosingOfPatientInClinicalTrialMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponCompletionOfFirstClinicalTrialMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponCompletionOfFirstClinicalTrialMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFdaNdaApprovalMember\nalzn:AL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFdaNdaApprovalMember\nalzn:AL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponINDApplicationFilingMember\nalzn:ALZN002LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponINDApplicationFilingMember\nalzn:ALZN002LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponCompletionOfFirstPhaseIIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponCompletionOfFirstPhaseIIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember\nalzn:ALZN002LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFDABLAApprovalMember\nalzn:ALZN002LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFDABLAApprovalMember\nalzn:ALZN002LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember\nalzn:AdditionalAL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:UponFirstPatientTreatedInAPhaseIIIClinicalMember\nalzn:AdditionalAL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:FirstCommercialSaleMember\nalzn:AdditionalAL001LicenseMember\n\n2026-04-30\n\n0001677077\n\nalzn:FirstCommercialSaleMember\nalzn:AdditionalAL001LicenseMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2024-01-31\n\n0001677077\n\nalzn:SeriesBConvertiblePreferredStockMember\nalzn:SecuritiesPurchaseAgreementsMember\nalzn:AultLendingMember\n\n2024-01-01\n2024-01-31\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2023-05-01\n2024-04-30\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2024-04-30\n\n0001677077\n\nus-gaap:SeriesBPreferredStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\nalzn:SecuritiesPurchaseAgreementsMember\nalzn:OrchidFinanceMember\n\n2025-02-01\n2025-02-28\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-02-28\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-04-01\n2025-04-28\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-05-01\n2025-05-29\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-06-02\n2025-06-03\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-06-10\n2025-06-12\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-06-11\n2025-06-13\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nus-gaap:SeriesCPreferredStockMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nalzn:October2024ATMMember\n\n2024-05-01\n2025-04-30\n\n0001677077\n\nalzn:March2026ATMMember\n\n2025-05-01\n2026-04-30\n\n0001677077\n\nus-gaap:SubsequentEventMember\n\n2026-05-01\n2026-07-22\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n \n\n****\n\n \n\n**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-K**\n\n \n\n**x****ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\n**For the Fiscal Year Ended April 30, 2026**\n\n \n\n**¨****TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF**\n\n \n\n**For the transition period from\n_______________ to _______________**\n\n \n\nCommission file number 001-40483\n\n** **\n\n**ALZAMEND NEURO, INC.**\n\n(Exact name of registrant\nas specified in its charter)\n\n \n\n**Delaware**\n**81-1822909**\n\n(State or other jurisdiction of incorporation or organization)\n (I.R.S. Employer Identification Number)\n\n \n \n\n \n\n**3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA**\n**30326**\n**(844) 722-6333**\n\n(Address of principal executive offices)\n(Zip Code)\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered under Section 12(b) of the\nAct:\n\n \n\n**Title of Each Class**\n**Trading Symbol**\n**Name of each exchange on which registered**\n\n**Common Stock, $0.0001 par value per share**\n**ALZN**\n**NASDAQ Capital Market**\n\n \n\nSecurities registered under Section 12(g) of the\nAct:        None\n\n \n\nIndicate by check mark if the registrant is a\nwell-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes  **¨**    No  x\n\n \n\nIndicate by check mark if the registrant is not\nrequired to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes  **¨**    No  x\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the\npreceding year (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such\nfiling requirements for the past 90 days. Yes  x    No  **¨**\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  x    No  **¨**\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer  **¨**\nAccelerated filer  **¨**\n\nNon-accelerated filer  x\nSmaller reporting company  x\n\nEmerging growth company  ¨\n \n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. **¨**\n\n \n\nIndicate by check mark whether the registrant\nhas filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial\nreporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or\nissued its audit report. **¨**\n\n \n\nIf securities are registered\npursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing\nreflect the correction of an error to previously issued financial statements. **¨**\n\n \n\n  \n\n \n\n \n\nIndicate by check mark\nwhether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by\nany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ¨    No  x\n\n \n\nThe aggregate market value of the common stock\nheld by non-affiliates of the registrant, based on the closing price of the shares of common stock on October 31, 2025 (the last business\nday of the registrant’s most recently completed second fiscal quarter), as reported by The Nasdaq Stock Market LLC on such date\nwas approximately $9.6 million. Shares of the registrant’s common stock held by each executive officer and director and by each\nother person who may be deemed to be an affiliate of the registrant have been excluded from this computation. This calculation does not\nreflect a determination that certain persons are affiliates of the registrant for any other purpose.\n\n \n\nThere were 4,791,525 shares of common stock outstanding\nas of July 22, 2026.\n\n \n\n**Documents incorporated by reference:**None\n\n \n\n \n\n  \n\n \n\n \n\n**ALZAMEND NEURO, INC.**\n\n** **\n\n**FORM 10-K**\n\n** **\n\n**FOR THE FISCAL YEAR ENDED APRIL 30, 2026**\n\n \n\n**INDEX**\n\n \n\n \n \n \n**Page**\n\n**PART I**"}